The programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) have shown positive efficacy in several solid cancers due to their targeted antitumour effects. However, the frequency and clinical implication value in prostate cancer still remain unclear.
Targeting androgen signaling with the second-generation anti-androgen drugs, such as enzalutamide (Enza), abiraterone (Abi), apalutamide (Apal), and darolutamide (Daro), is the mainstay for the treatment of castration-resistant prostate cancer (CRPC).
The assistance of robotic systems raises the concern of whether there is an improved learning in robotic-assisted radical prostatectomy (RARP) compared to open retropubic radical prostatectomy (ORP).
To determine whether or not decision aid (DA) use influences treatment decisions in patients with low and intermediate risk prostate cancer (PC). In a cluster randomized controlled trial, patients were randomized to either DA use (DA group) or no DA use (control group).
Urothelial carcinoma is one of the most common cancers in the United States, yet outcomes are historically suboptimal. Since 2016, the approval of five programmed cell death 1 and programmed death-ligand 1 immune checkpoint inhibitors for locally advanced and metastatic urothelial carcinoma has led to improved oncologic outcomes for many patients in the second-line setting.
Despite bladder perforation (BP) is a frequent complication during transurethral resection of bladder (TURB) for bladder cancer (BCa), literature lacks systematic reviews focusing on this issue. We aimed to investigate incidence, diagnosis, therapy, and prognosis after BP during TURB for BCa; therapy was distinguished between conservative (without the need for bladder repair) and surgical management […]
This paper presents our first experience with selective suturing or sutureless robot-assisted partial nephrectomy (RAPN). In this study we showed the feasibility and safety of this technique, is associated with intraoperative and postoperative complication rates in line with reports presented in the literature,1–3 a shorter operative time and promising results for the trifecta and functional […]
Bladder cancer remains one of the most expensive cancers to manage. Newer technologies and medications further compound costs of care. Blue light cystoscopy (BLC) has been traditionally offered in the inpatient setting, however, in-office applications are available.
A two-week scholarship in the USA for European Onco-Urologists For the EAU-SUO Scholar Exchange Programme, each medical association may send one of its members for a two-week scholarship at a department of choice before or after the respective association’s Annual Meeting. The Scholarship In 2021, the visit will take place for two weeks after the […]
The CROES Nephrolithometry nomogram, S.T.O.N.E. Nephrolithometry Score and Guy’s stone score were introduced for stratification of kidney stones disease on the basis of quantitative stone burden and its distribution.
